ClinicalTrials.gg
Not yet recruitingNCT07347236MyNOURISHUpdated Jan 16, 2026

MyNOURISH: Hydrolysed Collagen Supplementation in Older Adults With Fragility Fractures

An interventional study of Hydrolysed Collagen (PROTÉGEN Plus) and Standard Multidisciplinary Care in Fragility Fracture, sponsored by Hospital Pengajar Universiti Putra Malaysia. Not yet recruiting at 1 site in Malaysia. Open to participants aged 60 Years and older. Per ClinicalTrials.gov, last updated 2026-01-16.

Sponsored by Hospital Pengajar Universiti Putra Malaysia · Not applicable, Interventional, and Supportive care

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
76
Allocation
Randomized
Ages
60 Years and older
Sex
All
01

Study summary

The goal of this clinical trial is to learn whether hydrolysed collagen supplementation (PROTÉGEN Plus) within multidisciplinary care can improve nutrition and recovery in older adults with fragility fractures.

The main questions this study aims to answer are:

  1. Does collagen supplementation improve malnutrition status, nutritional biomarker (albumin levels), body composition (skeletal muscle and fat-free mass), functional capacity and bone turnover (P1NP and CTX) over 12 weeks intervention period?
  2. Does hydrolysed collagen supplementation have additional effects on the malnutrition status and functional capacity among older adult outpatients with fragility fractures at Week 6?
  3. Are the effects of hydrolysed collagen supplementation on the malnutrition status, nutritional biomarker (albumin), body composition (skeletal muscle and fat-free mass), functional capacity, and bone turnover biomarkers (P1NP and CTX) sustained up to 24 weeks post-intervention compared to standard care?

Researchers will compare two groups of older adults (aged 60 years and above) receiving care at Hospital Sultan Abdul Aziz Shah (HSAAS), Universiti Putra Malaysia:

- Intervention group: Participants will receive hydrolysed collagen (PROTÉGEN Plus) with usual care within a multidisciplinary team for 12 weeks.

Attend study visits at baseline, week 6, week 12, and week 24 (for follow-up of sustained effects). Keep a diary to record supplement intake, adherence, and any side effects, and return unopened supplement sachets at week 6 and 12 to monitor compliance.

- Control group: Participants will receive usual care within a multidisciplinary team. Attend study visits at baseline, week 6, week 12, and week 24 (for follow-up of sustained effects).

This study will help researchers understand whether adding tilapia-derived collagen supplementation to multidisciplinary care can support better nutrition, muscle and bone health, and long-term recovery in older adults after a fragility fracture. It is hoped that the findings will strengthen the evidence for incorporating targeted nutritional strategies as part of fragility fracture management and secondary fracture prevention.

02

Conditions studied

  • Fragility Fracture
03

In context

Lead sponsor

Hospital Pengajar Universiti Putra Malaysia is the lead sponsor of 7 studies on the registry; 5 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
60 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Male or female participants aged 60 years and above.
  • History of a fragility fracture (e.g., hip, wrist, or vertebral fracture) sustained within the past 12 months.
  • Registered outpatient at Hospital Sultan Abdul Aziz Shah (HSAAS).
  • Malaysian citizen.
  • Able to communicate in Bahasa Malaysia or English.
  • Able and willing to provide written .
  • Cognitive function score >4 on the Elderly Cognitive Assessment Questionnaire (ECAQ).
  • Currently undergoing a structured rehabilitation programme.
  • May be receiving antiresorptive osteoporosis therapy or not receiving any osteoporosis pharmacological treatment at the time of recruitment.

Exclusion criteria

Exclusion Criteria:

  • Cognitive impairment, defined as ECAQ score ≤4
  • Metabolic bone diseases other than osteoporosis (e.g., Paget's disease, osteomalacia).
  • Severe endocrine or metabolic disorders affecting bone metabolism (e.g., primary hyperparathyroidism, Cushing's syndrome, hyperthyroidism, hypogonadism, acromegaly).
  • Terminal illness or palliative care needs (e.g., advanced cancer, end-stage organ failure, late-stage neurodegenerative diseases).
  • Known allergy to fish, seafood, or collagen supplements, or diagnosis of phenylketonuria.
  • Kidney disease, including history of kidney stones or chronic kidney disease stage 4-5 (estimated \<44 mL/min/1.73 m²).
  • Participation in another interventional study that may interfere with the study protocol.
  • Use of nutritional supplements during the study period.
  • Prior use of collagen or amino acid-based supplements within the past 6 months.
  • Non-ambulatory status prior to the fracture.
  • Unstable medical conditions (e.g., uncontrolled arrhythmias, recent myocardial infarction, unstable angina, uncontrolled hypertension, pulmonary embolism).
  • Current use of anabolic osteoporosis therapy.
  • Alcohol dependence or active alcoholism.
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

05

Study design

Phase
Not applicable
Primary purpose
Supportive care
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
76 participants (estimated)

Study arms

  • Experimental
    Intervention Group (Hydrolysed Collagen supplement)

    Participants in this group will receive 15 g of hydrolysed tilapia collagen (PROTÉGEN Plus) daily for 12 weeks. Participants will attend follow-up assessments at baseline, week 6, week 12, and week 24 to monitor adherence, safety, and outcomes. Unopened supplement sachets will be returned at week 6 and 12 to assess compliance.

    Dietary Supplement: Hydrolysed Collagen (PROTÉGEN Plus)

  • Active comparator
    Control Group (Standard Multidisciplinary Care)

    Participants receive standard multidisciplinary care without collagen supplementation.

    Other: Standard Multidisciplinary Care

Interventions

  • Dietary supplementHydrolysed Collagen (PROTÉGEN Plus)

    Participants will receive 15 g of hydrolysed tilapia collagen (PROTÉGEN Plus) daily for 12 weeks, in addition to usual care provided within a multidisciplinary team approach.

  • OtherStandard Multidisciplinary Care

    Usual care consists of routine medical, nutritional, and rehabilitation management delivered through a multidisciplinary team approach at HSAAS, including follow-up medical reviews by physicians, personalised dietary counselling by dietitians, and tailored rehabilitation sessions conducted by physiotherapists.

06

What researchers measure

Primary outcomes

  1. Malnutrition status

    Malnutrition status will be assessed using the Mini Nutritional Assessment-Short Form (MNA-SF). The score categorizes participants as well-nourished, at risk of malnutrition, or malnourished. The study will evaluate the improvement in malnutrition status through the scoring on each timepoints, following hydrolysed collagen supplementation compared with standard multidisciplinary care.

    Time frame: Baseline, Week 6, Week 12, and Week 24 (follow-up for sustainability of effects)

Secondary outcomes

  1. Nutritional Biomarker (Serum albumin level)

    Serum albumin concentration will be measured from fasting blood samples to assess improvement in nutritional biomarker status. Increased albumin levels indicate improved protein status following hydrolysed collagen supplementation compared with standard multidisciplinary care.

    Time frame: Baseline, Week 12, and Week 24 (follow-up for sustainability of effects)

  2. Body composition (skeletal muscle mass and fat-free mass)

    Body composition-including skeletal muscle mass and fat-free mass-will be measured using bioelectrical impedance analysis (BIA). Changes will reflect improvement in overall muscle and bone tissue composition among older adults receiving hydrolysed collagen supplementation compared with standard multidisciplinary care.

    Time frame: Baseline, Week 12, and Week 24 (follow-up for sustainability of effects)

  3. Functional capacity-Change in Short Physical Performance Battery (SPPB) score

    Functional capacity will be assessed using the Short Physical Performance Battery (SPPB). These measures evaluate lower-extremity performance, balance, gait speed, and upper-body strength, collectively reflecting participants' physical function and rehabilitation progress. The SPPB consists of three components: balance tests, gait speed, and repeated chair stands. Scores range from 0 to 12, with higher scores indicating better physical performance. Improvements in these outcomes will be used to determine the added effect of hydrolysed collagen supplementation compared with standard multidisciplinary care alone.

    Time frame: Baseline, Week 6, Week 12, and Week 24 (follow-up for sustainability of effects)

  4. bone turnover biomarkers - Change in serum procollagen type I N-terminal propeptide (P1NP) levels

    Serum procollagen type I N-terminal propeptide (P1NP) will be measured as a marker of bone formation. Changes in P1NP levels reflect the bone synthesis. Improvements indicate enhanced bone metabolism following hydrolysed collagen supplementation compared with standard multidisciplinary care

    Time frame: Baseline, Week 12, and Week 24 (follow-up for sustainability of effects)

  5. Functional capacity - Change in handgrip strength

    Handgrip strength will be assessed using a hand-held dynamometer as a measure of muscle strength. Measurements will be obtained from the dominant hand, with the average of three trials recorded. Higher values indicate greater muscle strength. Units of measure is in Kilogram (Kg)

    Time frame: Baseline, Week 6, Week 12, and Week 24 (follow-up for sustainability of effects)

  6. Bone Turnover Biomarker - Change in serum C-terminal telopeptide of type I collagen (CTX) levels

    Serum C-terminal telopeptide of type I collagen (CTX) will be measured as a biochemical marker of bone resorption. Changes in CTX reflect alterations in bone resorption following hydrolysed collagen supplementation compared with standard multidisciplinary care.

    Time frame: Baseline, Week 12, and Week 24

07

Study locations

1 site
  • Hospital Sultan Abdul Aziz Shah (HSAAS), Universiti Putra Malaysia
    Serdang, Selangor 43400, Malaysia
08

References and documents

Related links

Individual participant data

Plan to share: No

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Start is estimated for Jan 2026; primary completion for Mar 2027, 14 months later.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 21, 2025
First posted
Jan 16, 2026
StartEst.
Jan 2026
Primary completionEst.
Mar 2027
CompletionEst.
Jun 2027
Last update
Jan 16, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 16, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07347236
Lead sponsor
Hospital Pengajar Universiti Putra Malaysia
Responsible party
Sponsor
First posted
Jan 16, 2026
Start date
Jan 2026 (estimated)
Primary completion
Mar 2027 (estimated)
Completion
Jun 2027 (estimated)
Last update
Jan 16, 2026

Study contacts

Farah Raihana Ghazi, BSc (Nutrition), MSc (Clinical
Contact
raihanaghazi@gmail.com
+60162262615
Noraida Omar, BSc(Dietetics), Ph.D(Nutrition
Contact
noraidaomar@upm.edu.my
+60192252902
Noraida Omar, BSc(Dietetics), Ph.D(Nutrition
principal investigator · Department of Dietetics, Faculty of Medicine and Health Sciences, Universiti Putra Malaysia (UPM)

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Jan 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion